000284647 001__ 284647
000284647 005__ 20240229155054.0
000284647 0247_ $$2doi$$a10.1016/j.ygyno.2023.09.016
000284647 0247_ $$2pmid$$apmid:37820398
000284647 0247_ $$2ISSN$$a0090-8258
000284647 0247_ $$2ISSN$$a1095-6859
000284647 0247_ $$2altmetric$$aaltmetric:155285079
000284647 037__ $$aDKFZ-2023-02050
000284647 041__ $$aEnglish
000284647 082__ $$a610
000284647 1001_ $$aKöbel, Martin$$b0
000284647 245__ $$aSurvey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
000284647 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2023
000284647 3367_ $$2DRIVER$$aarticle
000284647 3367_ $$2DataCite$$aOutput Types/Journal article
000284647 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697095929_9790
000284647 3367_ $$2BibTeX$$aARTICLE
000284647 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284647 3367_ $$00$$2EndNote$$aJournal Article
000284647 520__ $$aInhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration in tubo-ovarian high-grade serous carcinoma (HGSC) is the genomic inactivation of neurofibromin 1 (NF1). The primary objectives of our study were to survey the prevalence of NF1 inactivation in the principal ovarian carcinoma histotype as well as to evaluate its associations with clinico-pathological parameters and key biomarkers including BRCA1/2 status in HGSC.A recently commercialized NF1 antibody (clone NFC) was orthogonally validated on an automated immunohistochemistry (IHC) platform and IHC was performed on tissue microarrays containing 2140 ovarian carcinoma cases. Expression was interpreted as loss/inactivated (complete or subclonal) versus normal/retained.Loss of NF1 expression was detected in 250/1429 (17.4%) HGSC including 11% with subclonal loss. Survival of NF1-inactivated HGSC patients was intermediate between favorable BRCA1/2 mutated HGSC and unfavorable CCNE1 high-level amplified HGSC. NF1 inactivation was mutually exclusive with CCNE1 high-level amplifications, co-occurred with RB1 loss and occurred at similar frequencies in BRCA1/2 mutated versus wild-type HGSC. NF1 loss was found in 21/286 (7.3%) endometrioid carcinomas with a favorable prognostic association (p = 0.048), and in 4/64 (5.9%) LGSC, mutually exclusive with other driver events.NF1 inactivation occurs in a significant subset of BRCA1/2 wild-type HGSC and a subset of LGSC. While the functional effects of NF1 inactivation need to be further characterized, this signifies a potential therapeutic opportunity to explore targeting NF1 inactivation in these tumors.
000284647 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000284647 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284647 650_7 $$2Other$$aHigh-grade serous carcinoma
000284647 650_7 $$2Other$$aNF1
000284647 650_7 $$2Other$$aOvarian cancer
000284647 7001_ $$aYang, Rui Zhe$$b1
000284647 7001_ $$aKang, Eun Young$$b2
000284647 7001_ $$aAl-Shamma, Zainab$$b3
000284647 7001_ $$aCook, Linda S$$b4
000284647 7001_ $$aKinloch, Mary$$b5
000284647 7001_ $$aCarey, Mark S$$b6
000284647 7001_ $$aHopkins, Laura$$b7
000284647 7001_ $$aNelson, Gregg S$$b8
000284647 7001_ $$aMcManus, Kirk J$$b9
000284647 7001_ $$aVizeacoumar, Frederick S$$b10
000284647 7001_ $$aVizeacoumar, Franco J$$b11
000284647 7001_ $$aFreywald, Andrew$$b12
000284647 7001_ $$aFu, YangXin$$b13
000284647 7001_ $$0P:(DE-HGF)0$$aReuss, David E$$b14
000284647 7001_ $$aLee, Cheng-Han$$b15
000284647 773__ $$0PERI:(DE-600)1467974-7$$a10.1016/j.ygyno.2023.09.016$$gVol. 178, p. 80 - 88$$p80 - 88$$tGynecologic oncology$$v178$$x0090-8258$$y2023
000284647 909CO $$ooai:inrepo02.dkfz.de:284647$$pVDB
000284647 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000284647 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000284647 9141_ $$y2023
000284647 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-19$$wger
000284647 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGYNECOL ONCOL : 2022$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-19
000284647 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-19
000284647 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000284647 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000284647 980__ $$ajournal
000284647 980__ $$aVDB
000284647 980__ $$aI:(DE-He78)B300-20160331
000284647 980__ $$aI:(DE-He78)HD01-20160331
000284647 980__ $$aUNRESTRICTED